PFE — All updates

11 entries loaded; 0 direction changes

Filter loaded records
“3 Stocks I Own - Research Platform Overview!”
$PFEBullish
AI summary · Pfizer, a 4% portfolio position, has security in its traditional business and scale, which should generate value over time; recent earnings are good and buybacks have resumed. Profits could reverse the decline behind the collapse, leaving a value-level, single-digit P/E, and over time PFE is expected to perform well. Reaching $10 EPS in 2028, or half that goal, at 12x would be a really good return; this is buying actual earnings, not past expectations.

Pfizer, we have started opening an investment center in it. It represents 4% of the portfolio, and I believe there is security in its traditional business, in the core links , the banks, everything, and the scale of the business there that should generate value over time.

There is always the possibility of a reversal of the profits that led to the stock's collapse, bringing it down to a value level and single-digit price-to-earnings ratios . Over time, it is expected to perform well.

They have returned to buyback operations , and recent earnings have been good. And if they manage to achieve their goal, or even half of it, let's say they reach $10 earnings per share in 2028 multiplied by 12, that's a really good return.

You're buying actual earnings , not past expectations that caused the stock to crash, but actual earnings.

Schwab NetworkPublished 2026-11-02
“Ted Weisberg on META Value Opportunity in AI, Going Long on Energy & Airlines”
$PFEBullish
Brian ShannonPublished 2026-10-20
“Brian Shannon on TraderTV Live 10/20/26”
$PFEBullish
Ale's World of StocksPublished 2026-10-16
“Pfizer Stock: How AI & $80 Billion Acquisition Spree Could Spark a Monster Rebound! 🚨”
$PFEBullish
AI summary · PFE is one of the best undervalued long-term opportunities: >6% dividend, payout ratio <60%, cost cuts; trades >50% below sector average P/E, below pre-pandemic and decade-ago levels despite revenue/profit beats. $80B acquisitions and AI should offset pandemic sales declines and surpass them.

Today, we will take a closer look at one of the biggest dividend-paying major companies in the market: Pfizer (its stock ticker symbol is PFE). At first glance, one might expect income investors to be impressed by its huge dividend payouts, its track record of consistently growing them, and even its very recent extremely low valuation .

However , it seems that Wall Street does not want to deal with this stock at the moment.

Brian ShannonPublished 2026-10-13
“Brian Shannon on TraderTV Live 10/13/26”
$PFEBullish
AI summary · PFE yields 7% and could be a long-term dividend investment; its weekly chart still struggles against the 2022 peak but that is a reasonable long-term basis, and the monthly chart is not as bad as it has been. It is starting to look good and pique interest; the 7% is available if a bottom ever comes.

Oh, you know what? And I heard you talking about dividends earlier. Perhaps Pfizer is one of the stocks people want to invest in. Okay. That is a dividend of 7%, and if you look at this weekly chart, you see that we are struggling with an anchor point from the 2022 peak, and that is a nice basis for the long term, and it is 7%.

So maybe that is a dividend investment. I would n't do it myself, you know, that's not my thing, but it's one that crossed my mind .

Ale's World of StocksPublished 2026-09-27
“Saudi Arabia is Secretly Loading Up on THESE 5 Stocks! 🚨”
$PFEBullish
AI summary · PFE offers lower valuation and >6% yield; market currently overlooks PFE despite past underperformance.

like Pfizer, for example, which is not only cheaper in price and valuation , but also generates more than 6% as a dividend yield, while Eli Lilly generates less than 1%. I understand that Pfizer's performance was very bad, certainly.

This is the argument that pessimists might make , but I actually think the market is largely overlooking it right now, while I can't say the same about Eli Lilly.

Parkev Tatevosian, CFAPublished 2026-09-17
“Is Pfizer an Excellent Dividend Stock to Buy? | PFE Stock Analysis”
$PFEBullish
AI summary · Pfizer is a buy; DCF fair value of $50 implies significant upside from current levels.

Pfizer's management team is already incorporating artificial intelligence to help accelerate drug discovery, which is one of the biggest bullish opportunities that I see with artificial intelligence in the total opportunity value it can add to humanity worldwide.

They're also using artificial intelligence to help optimize manufacturing yields and enhance the effectiveness of its commercial sales force, but I think the bigger opportunity is in drug discovery with these pharmaceutical companies.

Ale's World of StocksPublished 2026-09-12
“Every Stock I'm Buying in September 2026 (Huge Opportunities)”
$PFEBullish
AI summary · PFE is the best biotech for valuation and dividend; considered a solid long-term hold.

Um Fizer, you know, in my opinion, Fizer is like the best like biotech in terms of an overall package valuation dividend wise right now. So, yeah, we're we are a little heavy on it, but I think that's okay. It's only around 4% of the portfolio.

So, Fizer, again, it's like the overall best biotech in terms of valuation and dividend. I think it's a solid biotech uh pharmaceutical play, whatever you want to call it,

Schwab NetworkPublished 2026-09-02
“Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities”
$PFEBullish
AI summary · PFE is a buy; downside protected by 6% yield and priced-in bad news, upside from oncology and GLP-1 pipeline.

I love it because it's so out of favor you can't give the stock away. Um you're getting a 6% dividend yield while you wait for them to turn the boat. They had a COVID windfall.

They used the money to buy CGEN 43 billion. That's going to do10 billion dollars a year. They cut 7.2 billion in cost. People are afraid of the loss of exclusivity from some of their major drugs.

It's lower than expected. And they have a GLP1 with the Metera coming out uh 2728, which is once a month GLP uh which you can take as a pill and subcutaneous. So maybe they'll be late to the party, maybe it'll be revolutionary.

We don't know. But in the meantime, costs are out. The oncology franchise pipeline is robust. All the bad news is priced in. You you got you're you know, I learned early on in this business, if your downside is protected, your upside will take care of itself.

And if I'm paid 6% to wait while this thing, you know, uh recovers over time. That's a good thing, not a bad thing.

What they said to watch for
DividendologyPublished 2026-08-11
“Insiders Buying Pfizer Stock at a 52 Week Low! | Pfizer (PFE) Stock Analysis! |”
$PFEBearish
AI summary · PFE is not a good buy now; dividend sustainability is questionable as payouts exceed FCF, and DCF analysis suggests significant downside despite insider buys.

A high-yield dividend stock just saw insiders start buying for the first time in over a year and a half, and I'm not going to make you wait to reveal the stock. It's Pfizer.

And Pfizer is a stock that's really struggled over the last few years. I've been covering it for a while now, but it's yielding around 6.4% at its current prices. However, I've pointed out some major concerns I have with the company at least over the last few years, and you can see the share price has been decimated.

If we look in the last 5 years, the stock is down by 41 nearly 42% in the last 6 months alone, down by 2.61%.

That's the earliest record
All updates for other tickers
Follow $PFE30-day free trial
Start trial